Associated Papers
Digital pathology and image analysis of p53 biomarker in lymphomas using two algorithms: correlation with genotype and visual inspection.
Naik A et al.
Journal of Clinical Pathology, 2025
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study.
Bignotti E et al.
International Journal of Cancer, 2025
39415516 (PubMed )
Supplement: IJC-156-1085-s004.xlsx › Mutations_detail
The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking.
Tsantikidi A et al.
Diagnostics (basel, Switzerland), 2023
37761329 (PubMed )
Supplement: diagnostics-13-02962-s001.zip › supplementary__Table_S2.xlsx › Table_S2_Samples_analyzed
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Palafox M et al.
Nature Communications, 2022
36071033 (PubMed )
Supplement: 41467_2022_32828_MOESM4_ESM.xlsx › Fig_2A_and_Table_S4
Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns.
Mateo L et al.
Genome Medicine, 2020
32907621 (PubMed )
Supplement: 13073_2020_774_MOESM1_ESM.zip › SupplementaryTables › TableS5.xlsx › Driver_Mutations
New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.
Garziera M et al.
Cells, 2019
31197119 (PubMed )
Supplement: cells-08-00584-s001.zip › Table_S1-1.xlsx › Foglio1
Comprehensive targeted super-deep next generation sequencing enhances differential diagnosis of solitary pulmonary nodules.
Ye M et al.
Journal of Thoracic Disease, 2018
Patterns and Biologic Features of p53 Mutation Types in Korean Breast Cancer Patients.
Kim HW et al.
Journal of Breast Cancer, 2014
A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
Lee Y et al.
The Journal of Pathology, 2007
Select a paper to view details